MAPBPIP Inhibitors
Chemical inhibitors of MAPBPIP are diverse in their mechanism of action but are unified in their outcome of diminishing the protein's function. PD 98059 and U0126 are selective inhibitors of MEK1 and MEK2, upstream regulators of MAP kinases. Their inhibition of MEK activity translates into reduced MAPK activity, which is essential for MAPBPIP function, leading to its functional inhibition. SB 203580 and PD 169316 specifically target p38 MAPK, and by doing so, they decrease the activity of MAPBPIP, which is linked to p38 MAPK signaling. Such targeted inhibition ensures that the protein's function is compromised by curtailing the signaling cascade it depends upon.
On the other hand, SP600125 and SL 327 inhibit JNK and MEK, respectively, both of which are integral to the MAPK pathway. The suppression of these kinases by SP600125 and SL 327 restricts the functional capacity of MAPBPIP. FR 180204 and BIRB 796, as ERK and p38 MAPK inhibitors, further demonstrate the strategy of blocking MAPBPIP activity by restraining the very pathways it is associated with. Sorafenib, a broad kinase inhibitor, also diminishes MAPBPIP's activity by broadly targeting multiple kinases within the MAPK pathway, thereby ensuring a downstream effect on MAPBPIP. Lastly, LY2228820, as a selective p38 MAPK inhibitor, exemplifies how the inhibition of specific kinases within a pathway can lead to a functional inhibition of proteins like MAPBPIP that are connected to those signaling processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 inhibits MEK, which is upstream of the MAPKs. As MAPBPIP is a part of the MAPK signaling cascade, inhibition of MEK by PD 98059 would result in reduced phosphorylation and activation of MAPKs, thereby inhibiting MAPBPIP's function that is dependent on this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2, upstream regulators of MAP kinases. By inhibiting these kinases, U0126 effectively reduces MAPK activity, which is essential for MAPBPIP function, hence functionally inhibiting MAPBPIP. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. As MAPBPIP is associated with MAPK signaling, inhibition of p38 MAPK by SB 203580 would lead to decreased activity of MAPBPIP that operates downstream of or in conjunction with the p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), part of the MAPK pathway. MAPBPIP, being associated with MAPK signaling, would have reduced functional activity due to the inhibition of JNK, which may be necessary for its full activity. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL 327 is an inhibitor of MEK, which is involved in MAPK/ERK pathway signaling. By inhibiting MEK, SL 327 impacts the MAPK/ERK pathway, leading to a reduction in MAPBPIP activity that relies on this signaling route. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
PD 169316 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, PD 169316 decreases MAPBPIP functional activity due to its reliance on p38 MAPK signaling for its function. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR 180204 is an ERK inhibitor. Since MAPBPIP is a part of the ERK/MAPK pathway, inhibition of ERK by FR 180204 directly decreases MAPBPIP's functional activity, which is contingent on ERK signaling. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 796 is a potent inhibitor of p38 MAPK. Inhibition of p38 MAPK by BIRB 796 would lead to a downstream reduction in MAPBPIP activity, as MAPBPIP's function is linked to the p38 MAPK pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that has been shown to inhibit several MAP kinases. Through this broad inhibition, it would decrease the activity of MAPBPIP by reducing the activity of kinases within the MAPK pathway that MAPBPIP depends on. | ||||||
LY2228820 | 862507-23-1 | sc-364525 | 5 mg | $191.00 | 1 | |
LY2228820 is a selective inhibitor of p38 MAPK. The inhibition of p38 MAPK by LY2228820 would functionally inhibit MAPBPIP activity, as it's linked to the signaling processes involving p38 MAPK. | ||||||